Novartis AG, apparently en route to recovery, is forecasting a return to growth next year driven by newly launched drugs, a bulging late-stage pipeline of promising therapies, and growth of new potential products.
That was the message from the Swiss group's second-quarter update July 18, which also saw a rebound in sales by...








